Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7301
    +0.0003 (+0.04%)
     

  • CRUDE OIL

    82.75
    -0.06 (-0.07%)
     

  • Bitcoin CAD

    88,427.64
    -2,897.34 (-3.17%)
     

  • CMC Crypto 200

    1,394.25
    -29.85 (-2.10%)
     

  • GOLD FUTURES

    2,330.60
    -7.80 (-0.33%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,480.25
    -184.25 (-1.04%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,965.70
    -494.38 (-1.29%)
     

  • CAD/EUR

    0.6819
    0.0000 (0.00%)
     

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

Myriad Genetics, Inc.
·1 min read
Myriad Genetics, Inc.
Myriad Genetics, Inc.

SALT LAKE CITY, May 04, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:20 p.m. EDT.

The presentation will be available through a live audio webcast link in the investor information section of Myriad’s website at www.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and commercializes genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.

ADVERTISEMENT

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Media Contact:

Investor Contact:

Megan Manzari

Nathan Smith

(385) 318-3718

(801) 505-5067

Megan.Manzari@myriad.com

Nathan.Smith@myriad.com